- Home
- LIXT vs RSLS Comparison
LIXT vs RSLS Comparison
Compare LIXT & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- RSLS
- Stock Information
- Founded
- LIXT 2005
- RSLS 2002
- Country
- LIXT United States
- RSLS United States
- Employees
- LIXT N/A
- RSLS N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- LIXT Health Care
- RSLS Health Care
- Exchange
- LIXT Nasdaq
- RSLS Nasdaq
- Market Cap
- LIXT 4.1M
- RSLS 4.5M
- IPO Year
- LIXT N/A
- RSLS 2007
- Fundamental
- Price
- LIXT $1.17
- RSLS $4.91
- Analyst Decision
- LIXT
- RSLS Hold
- Analyst Count
- LIXT 0
- RSLS 1
- Target Price
- LIXT N/A
- RSLS N/A
- AVG Volume (30 Days)
- LIXT 17.8K
- RSLS 348.2K
- Earning Date
- LIXT 05-12-2025
- RSLS 05-21-2025
- Dividend Yield
- LIXT N/A
- RSLS N/A
- EPS Growth
- LIXT N/A
- RSLS N/A
- EPS
- LIXT N/A
- RSLS N/A
- Revenue
- LIXT N/A
- RSLS $7,175,000.00
- Revenue This Year
- LIXT N/A
- RSLS $52.80
- Revenue Next Year
- LIXT N/A
- RSLS N/A
- P/E Ratio
- LIXT N/A
- RSLS N/A
- Revenue Growth
- LIXT N/A
- RSLS N/A
- 52 Week Low
- LIXT $1.02
- RSLS $4.34
- 52 Week High
- LIXT $3.50
- RSLS $414.99
- Technical
- Relative Strength Index (RSI)
- LIXT 41.14
- RSLS 36.83
- Support Level
- LIXT $1.28
- RSLS $4.34
- Resistance Level
- LIXT $1.41
- RSLS $5.01
- Average True Range (ATR)
- LIXT 0.12
- RSLS 0.54
- MACD
- LIXT -0.01
- RSLS 0.19
- Stochastic Oscillator
- LIXT 3.23
- RSLS 23.05
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.